<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924569</url>
  </required_header>
  <id_info>
    <org_study_id>6016-CONT</org_study_id>
    <nct_id>NCT04924569</nct_id>
  </id_info>
  <brief_title>Continence Care Registry (ConCaRe™)</brief_title>
  <official_title>Continence Care Registry (ConCaRe™)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hollister Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hollister Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational research study aims to build a multinational ePRO registry of adult end&#xD;
      users in outpatient and community settings using intermittent catheter(s) to void via the&#xD;
      urethra to manage urinary retention and incomplete bladder emptying. Research participants&#xD;
      will be asked to self-report on various attributes of their currently prescribed intermittent&#xD;
      catheters and other various aspects of using an intermittent catheter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This observational research study aims to build a multinational ePRO registry of adult end&#xD;
      users in outpatient and community settings using intermittent catheter(s) to void via the&#xD;
      urethra to manage urinary retention and incomplete bladder emptying. Research resulting from&#xD;
      data generated from an ePRO registry will factor in end user perspectives on intermittent&#xD;
      catheterization habits and behaviors and intermittent catheter performance to inform and&#xD;
      guide healthcare providers, end users, and caregivers in making the most informed healthcare&#xD;
      decisions regarding intermittent catheterization. Research participants will be asked to&#xD;
      self-report on various attributes of their currently prescribed intermittent catheters and&#xD;
      various aspects of habits and behaviors, including health-related quality of life, of using&#xD;
      an intermittent catheter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Creation of longitudinal continence care ePRO-based, direct-to-consumer registry</measure>
    <time_frame>5 years</time_frame>
    <description>To build a longitudinal continence care ePRO-based, direct-to-consumer registry addressing overall intermittent catheter product satisfaction, QoL, healthcare resource utilization associated with urinary symptoms, urinary tract infections and other complications, and associated factors to end-user product choice.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of intermittent catheterization habits and behaviours</measure>
    <time_frame>5 years</time_frame>
    <description>To identify intermittent catheterization habits and behaviors, via the analysis of the continence care registry data, to enable meaningful product-related and burden of illness insights and comparisons. Habits and behaviors include frequency of self-intermittent catheterization, catheter choice and access, intermittent catheter related complications, and adherence to catheterization plan.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Neurogenic Bladder</condition>
  <condition>Non-Neurogenic Neurogenic Bladder</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <description>Individuals using an intermittent catheter to void urine through the urethra. Participants use their currently prescribed intermittent catheter per their clinician's standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intermittent Catheter</intervention_name>
    <description>Flexible tubular device used to drain urine from the bladder via the urethra by male, female, and pediatrics.</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Sponsor-curated customer databases and printed EC/IRB approved advertisements targeted to&#xD;
        intermittent catheter consumers that may be distributed by clinicians, mail, website,&#xD;
        conferences and other consumer contacts.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is at least 18 years of age; male or female.&#xD;
&#xD;
          2. Is performing transurethral intermittent catheterization.&#xD;
&#xD;
          3. Uses intermittent catheter(s) from any manufacturer as a form of management for&#xD;
             urinary retention or incomplete bladder emptying.&#xD;
&#xD;
          4. Must be able to provide informed consent and have no cognitive impairment that would&#xD;
             hinder the ability to provide informed consent or self-reported data.&#xD;
&#xD;
          5. Is willing and able to complete electronic questionnaires in their preferred language&#xD;
             (English, German, French, Italian, or Dutch) monthly for the first year of data&#xD;
             collection and quarterly thereafter or appoint a caregiver proxy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Performs non transurethral catheterization, e.g., stoma.&#xD;
&#xD;
          2. Participating in a clinical study involving transurethral intermittent catheterization&#xD;
             at the time of enrollment.&#xD;
&#xD;
          3. Employee of Sponsor at the time of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacy Haddad, MS</last_name>
    <role>Study Director</role>
    <affiliation>Hollister Incorporated</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norma Thorelli, MD, MBA, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Hollister Incorporated</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Kearns, RGN, BA, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hollister Incorporated</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Kearns, RGN, BA, BSc</last_name>
    <phone>1-800-680-1000</phone>
    <email>barbara.kearns@hollister.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hollister Incorporated</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Kearns, RGN, BSPS</last_name>
      <phone>800-680-1000</phone>
      <email>barbara.kearns@hollister.com</email>
    </contact>
    <investigator>
      <last_name>Barbara Kearns, RGN, BSPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane Newman, DNP, FAAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intermittent Self Catheterization</keyword>
  <keyword>Intermittent catheter</keyword>
  <keyword>Urinary retention</keyword>
  <keyword>Urinary incontinence</keyword>
  <keyword>Urinary symptoms</keyword>
  <keyword>Urinary tract infection (UTI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

